News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Kevin E. Lofton Joins Gilead Sciences, Inc.'s Board of Directors
July 30, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Kevin E. Lofton has been appointed to the company’s Board of Directors, bringing the number of Directors to 12.
Twitter
LinkedIn
Facebook
Email
Print
People
Gilead Sciences, Inc.
MORE ON THIS TOPIC
China
AstraZeneca taps China’s CSPC again, betting up to $1.77B to target kidney diseases
July 2, 2026
·
2 min read
·
Tristan Manalac
Deals
Ipsen sends clear Memo to rare diseases with up to $796M buyout
July 1, 2026
·
2 min read
·
Gabrielle Masson
Manufacturing
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
July 1, 2026
·
2 min read
·
Nick Paul Taylor
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
·
2 min read
·
Jef Akst
